CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Methylphenidatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00018863
NCT00018863Phase 3Completed
CompareCT.gov

Methylphenidate Efficacy and Safety in ADHD Preschoolers

New York State Psychiatric Institute·interventional·Posted Jul 9, 2001·Updated Dec 2, 2020

In Brief

A Phase 3 clinical trial evaluating Methylphenidate for Attention Deficit Disorder With Hyperactivity. Completed, across 6 sites.

Detailed Summary

This research focuses on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in very young children. The medication being used is methylphenidate (Ritalin); it is being studied to determine its safety and how well it works to treat ADHD in preschool-age children (3-5.5 year olds).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Disorder With Hyperactivity
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 3CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 9, 2001
Enrollment StartApr 1, 2001
Primary CompletionMar 31, 2006
Study CompletionNov 30, 2006
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 25.0 years ago

Interventions

Methylphenidatedrug